SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- PMID: 36095062
- DOI: 10.1161/CIRCULATIONAHA.122.060805
SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
Keywords: Editorials; clinical trial; heart failure; metabolism; metabolomics; pharmacology.
Comment on
-
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.Circulation. 2022 Sep 13;146(11):808-818. doi: 10.1161/CIRCULATIONAHA.122.060402. Epub 2022 May 23. Circulation. 2022. PMID: 35603596 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
